Cryoport, Inc.
Cryoport Inc. (NASDAQ: CRYO) operates as a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with particular emphasis on the rapidly growing cell and gene therapy market. The company maintains its corporate website at www.cryoportinc.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cryoport, Inc. does
In the company’s own words
Cryoport Inc. (NASDAQ: CRYO) operates as a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with particular emphasis on the rapidly growing cell and gene therapy market. The company maintains its corporate website at www.cryoportinc.com.
The company delivers its integrated life sciences services and products through two reportable segments: Life Sciences Services, which accounts for 54.8 percent of total revenue, and Life Sciences Products, representing 45.2 percent of revenue. The Life Sciences Services segment encompasses four core solution areas: BioLogistics Solutions providing temperature-controlled transportation for critical biological materials; BioStorage Solutions delivering longer-term storage and value-added services through CryoGene operations; BioServices Solutions offering integrated storage, kitting, fulfillment and manufacturing support; and Cryopreservation Services through the IntegriCell platform for standardized cryopreservation of cellular starting materials. The Life Sciences Products segment includes cryogenic systems manufacturing through MVE Biological Solutions, which designs and manufactures cryogenic freezers, dewars, and transport systems.
Cryoport's integrated platform combines advanced logistics, biostorage, kitting and labeling, clinical sample management, and an industry-leading informatics platform centered on the Cryoportal digital logistics management system. The company operates a Global Supply Chain Center Network across the Americas, Europe, the Middle East and Africa, and Asia-Pacific regions, supported by a qualified partner network of transportation providers. As of December 31, 2025, Cryoport supported 760 clinical trials and 20 commercially approved cell and gene therapies.
The company employs 738 team members across its global operations, with 448 located in the Americas, 148 in EMEA, and 142 in APAC. Cryoport serves biopharmaceutical and pharmaceutical companies, contract research organizations, contract development and manufacturing organizations, central laboratories, fertility clinics, animal health companies, universities, and research facilities. The company maintains proprietary intellectual property including approximately 74 issued patents and more than 110 pending patent applications, along with registered trademarks protecting key service brands and product names. In 2025, Cryoport completed the divestiture of its CRYOPDP specialty courier business to DHL Supply Chain International Holding B.V., establishing a strategic partnership to enhance capabilities in EMEA and APAC regions.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BRENTWOOD, TN
- Fiscal year end
- December
- CIK
- 1124524
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cryoport, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cryoport, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Cryoport, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Cryoport, Inc.’s debt, $2.14M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.75%, maturing 2026 to 2026.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cryoport, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cryoport, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cryoport, Inc.'s last four quarterly filings that the numbers alone won't show?”